CEL-SCI's Phase III Head and Neck Cancer Trial Achieves Milestone; Delcath To Report 2nd Quarter 2014 Results on August 6th. Print E-mail
By Staff and Wire Reports   
Friday, 01 August 2014 18:44
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 31, 2014.
CEL-SCI Corporation (NYSE MKT: CVM) announced during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).  A total of 47 patients were enrolled over the past three months, with 14 in May, 19 in June, and 14 in July. This marks a 15% increase over the prior three month period when a total of 41 patients were enrolled.

“We reached an important milestone in July with total patient enrollment reaching 232, which is over one-quarter of the total 880 patients we expect to enroll by the end of 2015. We are on track with the pace of enrollment, which should accelerate in the fall based on the increasing number of clinical centers joining our study,” stated CEL-SCI Chief Executive Officer Geert Kersten.  “In the past three months alone, we have received clearances to expand the trial into the United Kingdom, Austria, Sri Lanka, Turkey and France, while we also continue to add clinical sites in North America.”


Delcath Systems, Inc. (NASDAQ: DCTH)
today announced that it will host a conference call and webcast on Wednesday, August 6, 2014 at 4:30 p.m. ET to discuss its financial results for the second quarter of 2014 ended June 30, 2014, and provide an update on recent corporate progress.

The dial-in numbers for the conference call are 877-703-6105 (U.S. participants) and 857-244-7304 (international participants); both numbers require passcode: 33935953. To access the live webcast, go to the Events & Presentations page on the Investor Relations section of the Company's website at http://www.delcath.com/investors/events/.

A taped replay of the call will be available beginning approximately two hours after the call's conclusion and will be available for seven days. Dial-in numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode for both U.S. and International callers is 93152789.  An archived webcast will also be available at http://www.delcath.com/investors/events/.

Also Friday:

Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS)
, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused Coalition for Concussion Treatment Summit.

Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS)
, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test®, currently under development for Alzheimer's disease diagnosis.

Analogic Corporation (Nasdaq:ALOG)
, enabling the world's medical imaging and aviation security technology, today announced results for its third quarter ended April 30, 2013.

Bacterin International Holdings, Inc. (NYSE MKT:BONE)
, a leader in the development of bone graft material and coatings for medical applications, today announced the pricing of its previously announced underwritten public offering.

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA)
, announced top-line data from a randomized, double-blind, placebo-controlled, parallel-arm Phase 2 clinical trial comparing the safety and efficacy of a 40 mg and 80 mg dose of laninamivir octanoate ("LANI") to placebo.

Celladon Corporation (Nasdaq:CLDN),
a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) and its affiliate lenders.

Coronado Biosciences, Inc. (Nasdaq:CNDO)
, a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that George Avgerinos, Ph.D. has joined the Company as Senior Vice President, Biologics Operations.

Ekso Bionics Holdings, Inc. (OTCQB:EKSO)
a robotic exoskeleton company, today announced that CEO Nathan Harding will be interviewed live by host Kelly Evans on CNBC Network's Closing Bell.

Foundation Healthcare Inc. (OTCQB:FDNH)
, an owner and operator of surgery focused hospitals that facilitate and enhance the surgical experience for surgeons and their patients, announced today it will host an earnings call to discuss the Company's second quarter 2014 financial results at 4:30 p.m. EDT (3:30 p.m. CDT) on Tuesday, August 12, 2014.

iKang Healthcare Group, Inc. (Nasdaq:KANG)
, the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, today announced that its Board of Directors has named Ms. Qing Liu as an independent director of the Company, effective July 31, 2014.

announced today that the Company will release its 2014 second quarter financial results before the market opens on Tuesday, August 12th.

MRI Interventions, Inc. (OTCQB:MRIC)
announced today that it will release its first quarter 2013 financial results on Thursday, May 9, 2013, after the close of the U.S. financial markets.

SGI (Nasdaq:SGI)
, the trusted leader in technical computing, today announced that Translational Research Institute (TRI) has selected SGI to provide a big data HPC solution powered by SGI® UV™ 2000 shared memory platform, SGI® Rackable® clusters and SGI® InfiniteStorage™ to accelerate results at its new state-of-the-art research centre.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus